Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer
NCT ID: NCT00210236
Last Updated: 2025-10-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
625 participants
INTERVENTIONAL
1995-09-30
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
NCT00072293
Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer
NCT01508546
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer
NCT00002528
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer
NCT00002720
Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery
NCT02466737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary aim is to assess if it is possible to avoid routine Axillary Lymph Node Excision during the initial treatment of breast cancers smaller than 11 mm in women aged 50 and older without compromising survival? The primary endpoint is overall survival: the event considered will be death from any cause.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional surgery WITH Axillary Lymph Node Excision
Tumorectomy or mastectomy, WITH Axillary Lymph Node Excision
Conventional surgery WITH Axillary Lymph Node Excision
Conventional surgery WITHOUT Axillary Lymph Node Excision
Tumorectomy or mastectomy, WITHOUT Axillary Lymph Node Excision
Conventional surgery WITHOUT Axillary Lymph Node Excision
Tumorectomy or mastectomy, WITHOUT Axillary Lymph Node Excision
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conventional surgery WITHOUT Axillary Lymph Node Excision
Tumorectomy or mastectomy, WITHOUT Axillary Lymph Node Excision
Conventional surgery WITH Axillary Lymph Node Excision
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
100 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Bergonié
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antoine AVRIL, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Bergonié
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire d'Agen
Agen, , France
Centre Régional de Lutte Contre le Cancer d'Anger
Angers, , France
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, , France
Centre Régional de Luttre Contre le Cancer de Clermont Ferrand
Clermont-Ferrand, , France
Centre Régional de Luttre Contre le Cancer de Dijon
Dijon, , France
Centre Régional de Luttre Contre le Cancer de Lille
Lille, , France
Centre Régional de Lutte Contre le Cancer de Lyon
Lyon, , France
Centre Hospitalier Intercommunal de Marmande
Marmande, , France
Centre Régional de Luttre Contre le Cancer de Montpellier
Montpellier, , France
Clinique de la Source
Orléans, , France
Centre Régional de Luttre Contre le Cancer de Nantes
Saint-Herblain, , France
Centre Hospitalier Universitaire de Saint Nazaire
Saint-Nazaire, , France
Centre Régional de Luttre Contre le Cancer de Strasbourg
Strasbourg, , France
Centre Regional de Lutte Contre le Cancer de Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Avril A, Le Bouedec G, Lorimier G, Classe JM, Tunon-de-Lara C, Giard S, MacGrogan G, Debled M, Mathoulin-Pelissier S, Mauriac L; AXIL95 Group. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up. Eur J Surg Oncol. 2011 Jul;37(7):563-70. doi: 10.1016/j.ejso.2011.04.008. Epub 2011 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IB1995-28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.